| [1] |
Huang HJ, Neven P, Drijkoningen M, et al. Association between tumor characteristics and HER2/neu by immunohistochemestry in 1362 women with primary operable breast cancer [J]. Clin Pathol, 2005, 58(6): 611-616.
|
| [2] |
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet, 2005, 365(9472): 1687-1717.
|
| [3] |
Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer(ABC2) [J]. Breast, 2014, 23(5): 489-502.
|
| [4] |
Schiavon G, Smith IE. Endocrine therapy for advanced/metastatic breast cancer [J]. Hematol Oncol Clin North Am, 2013, 27(4): 715-736.
|
| [5] |
Lønning PE, Eikesdal HP. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved [J]. Endocr Relat Cancer, 2013, 20(4): R183-201.
|
| [6] |
Miller WR, Bartlett J, Brodie AM, et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter？[J]. Oncologist, 2008, 13(8): 829-837.
|
| [7] |
Mauri D, Pavlidis N, Polyzos NP, et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis[J]. J Natl Cancer Inst, 2006, 98(18): 1285-1291.
|
| [8] |
Xu HB, Liu YJ, Li L. Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis[J]. Clin Breast Cancer, 2011, 11(4): 246-251.
|
| [9] |
Di Leo A, Jerusalem G, Petruzelka L, et al. Bondarenk results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2010, 28(30): 4594-4600.
|
| [10] |
Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST’ study[J]. Breast Cancer Res Treat, 2012, 136(2): 503-511.
|
| [11] |
Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase Ⅱ FIRST study[J]. J Clin Oncol, 2015, 33(32): 3781-3787.
|
| [12] |
Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer[J]. Nat Genet, 2013, 45(12): 1446-1451.
|
| [13] |
Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase Ⅲ TAnDEM study[J]. J Clin Oncol, 2009, 27(33): 5492-5494.
|
| [14] |
Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2014, 32(19): 2078-2099.
|
| [15] |
Narasimha AM, Kaulich M, Shapiro GS, et al. Cyclin D activates the Rb tumor suppressor by mono－phosphorylation[EB/OL]．[2016－08－19].
URL
|
| [16] |
Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast Cancer[J]. N Engl J Med, 2015, 373(3): 209-219.
|
| [17] |
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 Study [J]. Lancet Oncol, 2015, 16(1): 25-35.
|
| [18] |
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial[J]. Lancet Oncol, 2016, 17(4): 425-439.
|
| [19] |
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone receptor positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529.
|
| [20] |
Piccart M, Hortobahyi G, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: overall survival results from BOLERO-2[J]. Ann Oncol, 2014, 25(12): 2357-2362.
|
| [21] |
Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(＋) breast cancer: BOLERO-2 final progression-free survival analysis[J]. Adv Ther, 2013, 30(10): 870-884.
|
| [22] |
Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline[J]．J Clin Oncol, 2016, 34(25): 3069-3103.
|
| [23] |
Wolff A, Lazar A, Bondarenko I, et al. Randomized phase Ⅲ placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer[J]. J Clin Oncol, 2013, 31(2): 195-202.
|
| [24] |
Kümler I, Christiansen OG, Nielsen DL. A systematic review of bevacizumab efficacy in breast cancer[J]. Cancer Treat Rev, 2014, 40(8): 960-973.
|
| [25] |
Martín M, Loibl S, Von Minckwitz G, et al. Phase Ⅲ trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study[J]. J Clin Oncol, 2015, 33(9): 1045-1052.
|
| [26] |
Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials[J]. J Clin Oncol, 2001, 19(2): 343-353.
|
| [27] |
Carlson RW, Theriault R, Schurman C, et al. Phase Ⅱ trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women[J]. J Clin Oncol, 2010, 28(25): 3917-3921.
|
| [28] |
Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer[J]. N Engl J Med, 2014, 371(2): 107-118.
|